[A case of pulmonary metastasis from colon cancer responding completely to high-dose 5'-DFUR plus MMC combination chemotherapy].
A woman born in 1924 with colon cancer initially operated on approximately four years ago showed a second recurrence in the lung. Concomitant administration of high dose 5'-DFUR plus MMC was started in February, 1990. Chest X-ray examination six weeks after the start of this therapy revealed a remarkable decrease in size of the pulmonary metastatic focus. At 13 weeks after the start of this therapy, the pulmonary metastatic focus showed nearly complete disappearance. The condition above has been maintained until this writing, eight months after the start of this therapy. No recurrence has been observed in the liver and other organs either, while CEA has normalized from 17.6 ng/ml to 0.9 ng/ml. The therapy was discontinued after five courses based on the moderate loss of appetite and complete disappearance of the lung focus. No other side effect than the loss of appetite was detected, and could be safely treated at an outpatient clinic. The above findings suggested that this was an effective and safe therapy for pulmonary metastasis from colon cancers.
Kikkawa
N
N
Department of Surgery, Osaka National Hospital, Japan.
Tsuchiya
Y
Y
Tsumura
I
I
Kobayakawa
K
K
Kawahara
T
T
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D000284:Administration, Oral; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003110:Colonic Neoplasms / Q000473:pathology*; D004334:Drug Administration Schedule; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D016685:Mitomycin / Q000008:administration & dosage
D005467:Floxuridine; D016685:Mitomycin; C025034:doxifluridine